Investors who put money into Pfizer three years ago may be disappointed to learn they would have been better off with an S&P 500 index fund. However, Pfizer still offers a generous dividend and potential for growth. Despite past performance, Pfizer’s future looks promising with a pipeline of over 100 active programs. The company has been preparing for upcoming patent expirations and investing in new drugs. Pfizer also boasts a high dividend yield of 7%, making it an attractive option for investors. While past returns may not be impressive, the future outlook for Pfizer is positive.

Read more at Nasdaq: If You’d Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here’s How Much You’d Have Today